DDInter1934 DDInter1376
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Vilanterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Carvedilol
Vilanterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Vilanterol may lead to a major life threatening interaction when taken with Macimorelin
Vilanterol may lead to a major life threatening interaction when taken with Carvedilol